WO2002062207A3 - Myeloperoxidase, a risk indicator for cardiovascular disease - Google Patents

Myeloperoxidase, a risk indicator for cardiovascular disease Download PDF

Info

Publication number
WO2002062207A3
WO2002062207A3 PCT/US2002/000050 US0200050W WO02062207A3 WO 2002062207 A3 WO2002062207 A3 WO 2002062207A3 US 0200050 W US0200050 W US 0200050W WO 02062207 A3 WO02062207 A3 WO 02062207A3
Authority
WO
WIPO (PCT)
Prior art keywords
mpo
select
test subject
comprises determining
level
Prior art date
Application number
PCT/US2002/000050
Other languages
French (fr)
Other versions
WO2002062207A2 (en
Inventor
Stanley Hazen
Renliang Zhang
Original Assignee
Cleveland Clinic Foundation
Stanley Hazen
Renliang Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26947248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002062207(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cleveland Clinic Foundation, Stanley Hazen, Renliang Zhang filed Critical Cleveland Clinic Foundation
Priority to JP2002562218A priority Critical patent/JP4062514B2/en
Priority to BRPI0206273-9A priority patent/BR0206273A/en
Priority to AU2002249893A priority patent/AU2002249893B2/en
Priority to CA2440978A priority patent/CA2440978C/en
Priority to ES02718773T priority patent/ES2429528T3/en
Priority to DK02718773.1T priority patent/DK1353666T3/en
Priority to EP02718773.1A priority patent/EP1353666B1/en
Publication of WO2002062207A2 publication Critical patent/WO2002062207A2/en
Publication of WO2002062207A3 publication Critical patent/WO2002062207A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/26—Processes using, or culture media containing, hydrocarbons
    • C12N1/28—Processes using, or culture media containing, hydrocarbons aliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.
PCT/US2002/000050 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease WO2002062207A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2002562218A JP4062514B2 (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease
BRPI0206273-9A BR0206273A (en) 2001-01-02 2002-01-02 diagnostic tests to characterize a human patient's risk of developing or presenting cardiovascular disease and to evaluate a therapeutic agent for cardiovascular disease in a subject suspected of presenting or presenting cardiovascular disease;
AU2002249893A AU2002249893B2 (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease
CA2440978A CA2440978C (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease
ES02718773T ES2429528T3 (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease
DK02718773.1T DK1353666T3 (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease
EP02718773.1A EP1353666B1 (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25934001P 2001-01-02 2001-01-02
US60/259,340 2001-01-02
US28343201P 2001-04-12 2001-04-12
US60/283,432 2001-05-12

Publications (2)

Publication Number Publication Date
WO2002062207A2 WO2002062207A2 (en) 2002-08-15
WO2002062207A3 true WO2002062207A3 (en) 2002-10-31

Family

ID=26947248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000050 WO2002062207A2 (en) 2001-01-02 2002-01-02 Myeloperoxidase, a risk indicator for cardiovascular disease

Country Status (8)

Country Link
US (10) US7223552B2 (en)
EP (1) EP1353666B1 (en)
AU (1) AU2002249893B2 (en)
BR (1) BR0206273A (en)
CA (1) CA2440978C (en)
DK (1) DK1353666T3 (en)
ES (1) ES2429528T3 (en)
WO (1) WO2002062207A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440978C (en) 2001-01-02 2013-04-02 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
US7780950B2 (en) 2002-01-02 2010-08-24 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
CA2481941A1 (en) 2002-04-17 2003-10-30 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
US20050048660A1 (en) * 2003-09-02 2005-03-03 Case Western Reserve University Biomarker of maternal alcohol use during pregnancy
US7459286B1 (en) 2003-10-22 2008-12-02 The Cleveland Clinic Foundation Assessing the risk of a major adverse cardiac event in patients with chest pain
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
US20050244892A1 (en) * 2004-02-27 2005-11-03 Lazar Mitchell A Resistin as a marker and therapeutic target for cardiovascular disease
US7306562B1 (en) 2004-04-23 2007-12-11 Medical Software, Llc Medical risk assessment method and program product
US8852879B2 (en) * 2004-04-29 2014-10-07 The Children's Hospital Of Philadelphia Materials and methods for the detection of nitrated fibrinogen
US20050244905A1 (en) * 2004-04-29 2005-11-03 Harry Ischiropoulos Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation
EP1787116A4 (en) * 2004-07-19 2008-05-28 Univ Washington Methods for assessing the risk for development of cardiovascular disease
WO2006020498A2 (en) 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US7195891B2 (en) * 2004-08-11 2007-03-27 General Atomics Methods and compositions of enzymatic cycling based assays for myeloperoxidase
US20060183174A1 (en) * 2005-02-11 2006-08-17 Leong Ng Diagnosis
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
WO2009023331A2 (en) * 2007-05-18 2009-02-19 Abbott Laboratories Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
US20080286818A1 (en) * 2007-05-18 2008-11-20 Datwyler Saul A Blood sample handling methods for improved assays for myeloperoxidase
US20090148866A1 (en) * 2007-05-18 2009-06-11 Abbott Laboratories Antibodies and Improved Test Sample Handling Methods for Use in Assays for Myeloperoxidase
US20090134325A1 (en) * 2007-11-27 2009-05-28 Goldman Mildred M Methods for detecting estradiol by mass spectrometry
US8916385B2 (en) 2007-12-13 2014-12-23 Quest Diagnostics Investments, Inc. Methods for detecting estrone by mass spectrometry
US20090162876A1 (en) * 2007-12-20 2009-06-25 Abbott Laboratories Myeloperoxidase assays
US20090208992A1 (en) * 2008-02-20 2009-08-20 The Cleveland Clinic Foundation Paraoxonase 1 enzymatic activity, a risk indicator for major adverse cardiovascular events
WO2009114875A2 (en) * 2008-03-14 2009-09-17 The Cleveland Clinic Foundation Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2443456A4 (en) * 2009-06-15 2013-02-20 Cleveland Clinic Foundation Methylated arginine metabolites as risk predictors of cardiovascular disease
US20110034419A1 (en) * 2009-06-27 2011-02-10 Musc Foundation For Research Development Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease
WO2011100426A2 (en) * 2010-02-10 2011-08-18 Cleveland Heartlab Llc Compositons and methods for predicting cardiovascular events
EP2366431A1 (en) 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
US20110287468A1 (en) 2010-04-19 2011-11-24 General Atomics Methods and compositions for assaying enzymatic activity of myeloperoxidase in blood samples
JP5337096B2 (en) 2010-04-28 2013-11-06 株式会社日立製作所 Evaluation of arteriosclerosis
DK2385374T4 (en) 2010-05-05 2018-04-30 Zora Biosciences Oy LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE
CA2801459C (en) 2010-06-20 2018-04-24 Zora Biosciences Oy Lipidomic biomarkers for identification of high-risk coronary artery disease patients
GB201021509D0 (en) * 2010-12-20 2011-02-02 Reactivlab Ltd Assay method
KR101660328B1 (en) 2014-01-14 2016-09-27 한국과학기술연구원 Biomarker for diagnosis of cardiovascular disease
JP6724159B2 (en) 2016-04-01 2020-07-15 カーディアック ペースメイカーズ， インコーポレイテッド Alert management for physiological event detection
CA3035557A1 (en) * 2016-09-01 2018-03-08 The George Washington University Blood rna biomarkers of coronary artery disease
KR102003309B1 (en) 2016-12-05 2019-07-25 한국과학기술연구원 Kit for diagnosis of coronary heart disease using multi-metabolites and clinical parameters, and method for providing information for diagnosis of coronary heart disease using the same
US20180168779A1 (en) * 2016-12-19 2018-06-21 Sten R. Gerfast Anchoring system for prosthetics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122534A (en) * 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
US5889042A (en) * 1996-02-28 1999-03-30 Pfizer Inc. Method of treating diseases and conditions with estrogen agonists and antagonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2765299A (en) * 1952-06-27 1956-10-02 Armour & Co Recovery of serum albumin
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
FR2644894B1 (en) 1989-03-24 1994-05-13 Sanofi ENZYMATIC DOSAGE KIT AND METHOD APPLICABLE TO WHOLE CELLS
IT8921788A0 (en) 1989-09-21 1989-09-21 Diesse Diagnostica REAGENT USEFUL FOR THE DETECTION AND QUANTITATIVE DETERMINATION OF LEUKOCYTES IN BIOLOGICAL FLUIDS.
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US6962795B1 (en) * 1992-05-11 2005-11-08 Dendreon Corporation Neutrophil inhibitors
US6191169B1 (en) * 1992-08-28 2001-02-20 City Of Hope Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
WO1996004311A1 (en) * 1994-08-03 1996-02-15 University Of Alabama At Birmingham Research Foundation Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease
US5871946A (en) * 1995-05-18 1999-02-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5731208A (en) * 1996-09-09 1998-03-24 Washington University Method of detecting conditions indicative of atherosclerosis
US6268220B1 (en) * 1996-09-09 2001-07-31 Washington University Diagnostic method for atherosclerosis
US5874313A (en) * 1997-03-25 1999-02-23 Oy Aboatech Ab Method for quantifying oxidation parameters of low density lipoproteins and use thereof
US7030152B1 (en) * 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
ATE530180T1 (en) 1997-04-02 2011-11-15 Brigham & Womens Hospital METHOD FOR DETERMINING THE INDIVIDUAL RISK PROFILES OF ATHEROSCLEROTIC DISEASES
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6096556A (en) * 1998-02-09 2000-08-01 Washington University Method for the determination of oxidative stress
US6133039A (en) * 1998-02-09 2000-10-17 Washinton University In vivo method for determination of oxidative stress
US6953666B1 (en) * 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
DE60033380T2 (en) * 1999-03-29 2008-01-24 Asahi Kasei Kabushiki Kaisha METHOD FOR QUANTIFYING THE NUMBER OF LEUKOCYTES IN A BLOOD TEST
BR0115257A (en) * 2000-11-10 2003-08-12 Proteopharma Aps Apolipoprotein analogues
WO2002048715A2 (en) 2000-12-14 2002-06-20 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
BE1013881A6 (en) 2000-12-21 2002-11-05 Univ Bruxelles OXIDIZED LDL FRACTIONS, PROCESS FOR OBTAINING AND USE FOR DIAGNOSTIC OR THERAPEUTIC PURPOSE.
CA2440978C (en) * 2001-01-02 2013-04-02 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
US20030008373A1 (en) * 2001-04-17 2003-01-09 Myriad Genetics, Incorporated APOA1-interacting proteins and use thereof
CA2344007A1 (en) * 2001-04-12 2002-10-12 Michael R. Buchanan Cardiovascular disease and thrombotic risk diagnostic tests
WO2003026651A1 (en) * 2001-09-28 2003-04-03 Indevus Pharmaceuticals, Inc. Method of inhibiting the production and/or effects of intestinal pro-inflammatory cytokines, prostaglandins and others
US20120129708A1 (en) * 2010-05-19 2012-05-24 Cleveland Heart Lab Compositions and methods for predicting cardiovascular events

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122534A (en) * 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
US5889042A (en) * 1996-02-28 1999-03-30 Pfizer Inc. Method of treating diseases and conditions with estrogen agonists and antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HONG, J.H. ET AL.: "Supplementation with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats", HYPERTENSION, vol. 38, 2002, pages 1044 - 1048, XP002952174 *
MERTENS, A. ET AL.: "Oxidized LDL and HDL: antagonists in atherothrombosis", FASEB JOURNAL, vol. 15, no. 5, October 2001 (2001-10-01), pages 2073 - 2084, XP002952171 *
MOMII, H. ET AL.: "Inhibition of adhesion molecules markedly ameliorates cytokine-induced sustained mycocardial dysfunction in dogs in vivo", J. MOL. CELL CARDIOL., vol. 30, 1998, pages 2637 - 2650, XP002952173 *
PODREZ, A. ET AL.: "Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species", J. CLIN. INVEST., vol. 105, no. 8, April 2000 (2000-04-01), pages 1095 - 1108, XP002952172 *

Also Published As

Publication number Publication date
WO2002062207A2 (en) 2002-08-15
US20060105408A1 (en) 2006-05-18
ES2429528T3 (en) 2013-11-15
US20020164662A1 (en) 2002-11-07
US9612242B2 (en) 2017-04-04
EP1353666A2 (en) 2003-10-22
US20110152224A1 (en) 2011-06-23
US20110287449A1 (en) 2011-11-24
US20160238603A1 (en) 2016-08-18
DK1353666T3 (en) 2013-10-14
US9170260B2 (en) 2015-10-27
US20080009020A1 (en) 2008-01-10
US9435808B2 (en) 2016-09-06
CA2440978A1 (en) 2002-08-15
CA2440978C (en) 2013-04-02
EP1353666B1 (en) 2013-07-03
US9140703B2 (en) 2015-09-22
AU2002249893B2 (en) 2007-05-24
BR0206273A (en) 2006-11-21
US9575065B2 (en) 2017-02-21
US20160109448A1 (en) 2016-04-21
US20150185217A1 (en) 2015-07-02
US20160238604A1 (en) 2016-08-18
EP1353666A4 (en) 2004-03-31
US9164095B2 (en) 2015-10-20
US9581597B2 (en) 2017-02-28
US7223552B2 (en) 2007-05-29
US20160238605A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
WO2002062207A3 (en) Myeloperoxidase, a risk indicator for cardiovascular disease
Wright et al. Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor
Kuchnia et al. Phase angle and impedance ratio: reference cut‐points from the United States National Health and nutrition examination survey 1999–2004 from bioimpedance spectroscopy data
Touger et al. Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning
Rogoza et al. Validation of A&D UA-767 device for the self-measurement of blood pressure
Sung et al. The relationship between arterial stiffness and increase in blood pressure during exercise in normotensive persons
WO2000065366A8 (en) Nmr-method for determining the risk of developing type 2 diabetes
Alecu et al. Reference values of aortic pulse wave velocity in the elderly
Swain et al. Reproducibility of blood pressure and heart rate reactivity: A meta‐analysis
WO1999051142A3 (en) Non-invasive tissue glucose level monitoring
Sung et al. Exercise blood pressure response is related to left ventricular mass
Cozma et al. Determining factors of arterial stiffness in subjects with metabolic syndrome
Kroke et al. Blood pressure measurement in epidemiological studies: a comparative analysis of two methods. Data from the EPIC-Potsdam Study
Kanda et al. Arterial pulse wave velocity and risk factors for peripheral vascular disease
Bhuiyan et al. Distribution and correlates of arterial compliance measures in asymptomatic young adults: the Bogalusa Heart Study
Rice et al. Effects of diet on fecal occult blood testing in healthy dogs.
Zweiker et al. Comparison of wrist blood pressure measurement with conventional sphygmomanometry at a cardiology outpatient clinic
WO2001096864A3 (en) A method for detecting a lipoprotein-acute phase protein complex
Teramoto et al. Reference value of six-minute walking distance in healthy middle-aged and older subjects
Longo et al. Validation of the A&D UA-631 (UA-779 Life Source) device for self-measurement of blood pressure and relationship between its performance and large artery compliance
Jensen et al. Study on biological variability of haematological components in dogs
WO2002022859A3 (en) Assessment of ecosystem health by evaluating multiple biomarkers in a nonhuman organism
WO2003042701A3 (en) Method for diagnosing multiple sclerosis and an assay therefore
Longo et al. Performance of the UA-787 oscillometric blood pressure monitor according to the European Society of Hypertension protocol
MXPA03004286A (en) Method , system, and computer program product for measuring hematocrit in blood vessels.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002562218

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002718773

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002249893

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2440978

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002718773

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: PI0206273

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2002249893

Country of ref document: AU